Enodia Therapeutics has raised €20.7 million in seed funding to advance its innovative therapeutic platform targeting pathogenic proteins, backed by prominent investors and a strong foundational research base.

Target Information

Enodia Therapeutics, a startup born out of the Institut Pasteur and officially launched in February 2025, has recently announced a successful funding round of €20.7 million during its seed funding phase. This round was co-led by Elaia, Pfizer Ventures, and Bpifrance, under the InnoBio investment strategy, with additional participation from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest, and Mission BioCapital. The significant funding amount showcases the potential of the Pasteurian model in transforming fundamental research into groundbreaking therapeutic innovations.

The therapeutic platform developed by Enodia stems from research conducted at the Institut Pasteur. It leverages machine learning to selectively modulate the SEC61 translocon, a protein channel embedded in the endoplasmic reticulum membrane, which serves as the 'gateway' for cellular secretion. The startup's name, Enodia, references the Greek goddess who guards gates and protects against maladies. CEO Yves Ribeill states, “If we identify inhibitors that prevent pathogenic proteins from passing through this gateway, we effectively protect the host.” This approach allows for early intervention in diseases, ensuring vital physiological functions are not compromised before lesions appear.

Industry Overview in France

The biopharmaceutical industry in France is robust, characterized by a strong commitment to research and development. Home to numerous prestigious research institutions, like the Institut Pasteur, France is a leade